16 results on '"Chronic Urticaria"'
Search Results
2. [Care and medical costs of urticaria in children in Germany : Drugs, medical and inpatient services].
- Author
-
Staubach P, Mann C, Hagenström K, and Augustin M
- Subjects
- Humans, Child, Germany, Female, Male, Adolescent, Child, Preschool, Retrospective Studies, Infant, Infant, Newborn, Urticaria drug therapy, Urticaria economics, Health Care Costs statistics & numerical data, Hospitalization economics
- Abstract
Background: Data on the course of urticaria in children exist, but there is a lack of sound data on patient management to ensure high-quality care., Methods: Retrospective secondary data analysis in the field of health care and epidemiology in children with urticaria based on routine data from a German health insurance company (DAK-Gesundheit). Data from insured persons under 18 years of age who were treated as outpatients or inpatients with a diagnosis of urticaria (according to ICD-10 classification) in 2010-2015 were included. The control group consisted of children without a corresponding diagnosis, in order to clarify health economic and care-related differences after adjusting for age and gender., Results: In 2015, 1904 (1.3%) of 151,248 insured minors had a diagnosis of urticaria. Of the children with urticaria, 70.9% visited at least one physician on an outpatient basis. Of these visits, 70.9% were made to a pediatrician, 52.5% to a general practitioner and 33.0% to a dermatologist; 11% were treated as inpatients. With a total of 151,248 insured persons, 1904 of whom were diagnosed with urticaria, 72.9% of children and adolescents with versus 28.9% without urticaria were treated topically or systemically in 2015, including 10.5% of children with urticaria vs. 2.6% without urticaria received topical therapy and 70.0% with urticaria received systemic therapy vs. 27.5% without urticaria with systemic therapy. The most commonly used oral medications for urticaria were cetirizine (44.2%), prednisolone (9.8%), and dimetindene (2.0%) . Topical methylprednisolone aceponate (49.8%) was prescribed most frequently. The therapy costs for systemic drugs was € 24.00 per patient, while topical drugs cost € 1.58 per patient., Conclusion: The lack of guidelines for the standardization of treatment in children still leads to ambiguities and different treatment concepts among the specialist groups, which must be eliminated in order to enable more efficient therapies. The treatment of chronic urticaria in children and adolescents is mainly carried out by pediatricians, general practitioners and dermatologists. Systemic and topical medications as well as inpatient services are the most important cost factors., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. [Which augmentation and trigger factors are relevant in urticaria?]
- Author
-
Zarnowski J and Treudler R
- Subjects
- Humans, Chronic Disease, Inflammation, Comorbidity, Urticaria etiology, Chronic Urticaria
- Abstract
The aim of this review is to present relevant trigger as well as augmentation factors that can induce or exacerbate urticaria on the basis of a current, PubMed-based literature search. In addition to a brief description of relevant influencing factors in acute and chronic inducible urticaria, the focus will be on chronic spontaneous urticaria. In particular, the aggravating role of medication, stress, food, psychological and metabolic comorbidities, infections and inflammation as well as hormonal processes will be discussed., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Untersuchung der Komorbiditäten, Versorgungssituation und Fragen zur Lebensqualität bei Patienten mit cholinergischer Urtikaria
- Author
-
Mellerowicz, Emilia Juliane
- Subjects
cholinergic urticaria ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,real-world treatment ,chronic urticaria - Abstract
Aktueller Forschungsstand: Chronische Urtikaria ist eine der häufigsten dermatologischen Erkrankungen. Die cholinergische Urtikaria (cholU) gehört zu den chronischen induzierbaren Urtikariaformen. Ausgelöst durch Schwitzen kommt es zu charakteristischen stecknadelkopfgroßen, stark juckenden Quaddeln und in bis zu 50% auch zu Angioödemen. Gemäß der aktuellen EAACI/GA²LEN/EDF/WAO Leitlinie gliedert sich die Therapie der cholU in 4 Stufen: Erst- und Zweitlinientherapie sind Antihistaminika in einfacher und bis zu vierfacher Dosierung. Als Drittlinientherapie wird zusätzlich Omalizumab empfohlen; falls es darunter zu keiner Besserung kommt, kann eine Therapie mit Ciclosporin erwogen werden. Die vorliegende Studie erhebt erstmals Daten über die Versorgungsrealität von Patienten mit cholinergischer Urtikaria, die Umsetzung der Leitlinie von cholU Patienten im deutschsprachigen Raum und deren Wirksamkeit im alltäglichen Setting. Methodik: Mittels eines Online-Fragebogens in deutscher Sprache wurden 111 Patienten mit ärztlich gesicherter Diagnose einer cholU über ihre aktuelle Therapie, die Therapieerfolge und Nebenwirkungen befragt. Diese gewonnenen Daten wurden in SPSS übertragen und anschließend analysiert. Ergebnisse: Die große Mehrzahl der cholU Patienten (97%) wurden mit Antihistaminika therapiert, 87% davon mit nicht-sedierenden Antihistaminika (nsAH). Fast ein Viertel (23%) der cholU Patienten haben auch sedierende Antihistaminika (sdAH) eingenommen. Eine Symptomverbesserung unter einfacher Dosierung mit Antihistaminika trat selten auf (sdAH: 16% der Patienten, nsAH 32% der Patienten). Die Nebenwirkungen der verschiedenen Antihistaminika Präparate waren vergleichbar, am häufigsten trat Müdigkeit auf. 66 Patienten (59%) erhielten eine Aufdosierung der Antihistaminikatherapie, 98% davon mit nsAH. Das Therapieansprechen auf die erhöhte Dosis ergab keine signifikante Verbesserung im Vergleich zur einfachen Dosierung von nicht-sedierenden Antihistaminika, 38% im Vergleich zu 32%. Ein Drittel (30%) der Patienten wurde auch mit Kortiosteroiden behandelt, welche in den aktuellen Leitlinien nicht empfohlen werden. Nur 6 Patienten (5%) wurden zusätzlich mit Omalizumab therapiert. Diskussion: Die vorliegende Arbeit zeigt auf, dass die Erst- und Zweitlinientherapie derzeit größtenteils leitliniengerecht erfolgt, allerdings sind zwei Drittel der Patienten damit nicht suffizient behandelt. Deshalb wäre ein Ausbau der Versorgung mit Dritt- und Viertlinientherapie sinnvoll, was jedoch durch eine fehlende Zulassung von Omalizumab und Ciclosporin in der Indikation cholU erschwert ist. Die Studie zeigt einen hohen Bedarf an einem verbesserten Zugang zur Dritt- und Viertlinientherapie bzw. zu neuen Therapieformen, bei größtenteils unkontrollierten Symptomen der Patienten mit cholU., Background: Urticaria is one of the most common dermatological diseases. Cholinergic urticaria (cholU) belongs to the subgroup of chronic inducible urticaria. Induction of sweating leads to the characteristic strong itching, pinpoint sized wheals and in up to 50 % also to concomitant angioedema. According to the current EAACI/GA²LEN/EDF/WAO guideline recommendations, the therapy has a step-up approach: First-line are second generation antihistamines, second line these antihistamines updosed up to four times, as third- line Omalizumab is added and as fourth- line Ciclosporin can be a therapeutic alternative. Little is known about the cholU patients supply situation, their real-life treatment and if the treatment is following the current guideline recommendations in German speaking countries. Method: We collected, analysed and compared treatment, treatment success and adverse events of 111 patients, who took part in an online survey about cholinergic urticaria in German speaking countries. Results: Almost all cholU patients (97%) had used antihistamines, 87% of them second-generation antihistamines (sgAH). One in four cholU patients (23%) had also taken first-generation antihistamines (fgAHs). The rate of cholU patients who benefitted from standard-dosed antihistamine treatment was low (sgAHs: 32% vs. fgAHs: 16%). Side effects of the different Antihistamines were comparable, most common was fatigue. Updosing of antihistamines had been tried by 66 patients (59%); most commonly (98%) with sgAHs. Treatment responses with updosed sgAH were not significantly better than with standard-dosed sgAHs, with 38% vs 32% of patients reporting benefit. One-third (30%) of the cholU patients received corticosteroids as an alternative treatment, only 6 patients (5%) had reported treatment with Omalizumab. Discussion: Our study revealed that current treatment regimens for cholU patients are mostly aligned with the latest guideline recommendations; however, two-thirds of the patients are insufficiently treated. The use of third-and forth-line therapy should be improved. There is a need for education on and also investigation for alternative therapies, aiming for a better symptom control in these patients.
- Published
- 2020
5. Ausgewählte psychosomatische Aspekte in der dermatologischen Praxis.
- Author
-
Stumpf, A.
- Abstract
Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
- Full Text
- View/download PDF
6. Urtikaria.
- Author
-
Daut, V., Staubach, P., Hörmann, K., Klimek, L., and Pfaar, O.
- Abstract
Copyright of HNO is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
- Full Text
- View/download PDF
7. Omalizumab bei therapierefraktärer chronischer Urtikaria mit Angioödem.
- Author
-
Korkmaz, H., Eigelshoven, S., and Homey, B.
- Published
- 2010
- Full Text
- View/download PDF
8. Unverträglichkeiten als Folge einer Hyperreaktivität.
- Author
-
Pichler, W. J.
- Subjects
- *
INFLAMMATION , *IMMUNOGLOBULIN E , *IMMUNOLOGIC diseases , *FOOD allergy , *ANTIASTHMATIC agents , *URTICARIA , *DRUG allergy - Abstract
Many patients complain about hyperreactivity of the skin or mucosal membranes, whereby rather harmless «triggers» lead to exaggerated reactions like running nose, bronchospasm, urticaria, etc. Most of these hyperreactivities have an underlying inflammation. It is important not to focus only on the triggers, but to look for the agent causing the inflammation and to avoid/treat it: elimination of the cause also eliminates the hyperreactivity. Four examples are presented where this cause -- trigger model of hyperreactivity is illustrated (exercise induced asthma, pollen associated food allergy, flare-up reactions in drug allergy and hyperreactivity in chronic urticaria). [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
9. Urtikaria.
- Author
-
Magerl, M. and Maurer, M.
- Abstract
Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2007
- Full Text
- View/download PDF
10. Chronische Urtikaria im Kindesalter.
- Author
-
Wieczorek, D., Raap, U., Liekenbröcker, T., Kapp, A., and Wedi, B.
- Abstract
Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2004
- Full Text
- View/download PDF
11. Neue Therapieoptionen der Urtikaria und ihrer Subtypen.
- Author
-
Raap, U., Liekenbröcker, T., Wieczorek, D., Kapp, A., and Wedi, B.
- Abstract
Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2004
- Full Text
- View/download PDF
12. Innovative Therapien und neue diagnostische Verfahren bei chronischer Urtikaria
- Author
-
Ohanyan, Tatevik
- Subjects
Chronic Urticaria ,Innovative therapy ,Omalizumab ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,Mast cell ,Fcε-Rezeptor-I - Abstract
Die Urtikaria ist eine der häufigsten dermatologischen Erkrankungen. Die vorliegende Arbeit hatte zum Ziel neue Verfahren in der Diagnostik der chronischen Urtikaria (CU) zu validieren, die Effekte von Omalizumab als innovative Therapie der CU zu charakterisieren, sowie mögliche Prädiktoren für ein Therapieansprechen zu identifizieren. Hierfür wurden vier unabhängige Studien durchgeführt. In den ersten beiden Studien wurde die Wirksamkeit und Sicherheit einer Therapie mit Omalizumab bei Patienten mit CU klinisch evaluiert. Die beiden retrospektiven Studien konnten u.a. zeigen, dass 57% der Patienten mit chronischer spontaner Urtikaria (csU) bereits innerhalb der ersten Woche nach der ersten Behandlung beschwerdefrei waren, und dass Patienten nach Unterbrechung der Therapie mit Omalizumab und nach der erneuten Einleitung einer Behandlung wieder nach kurzer Zeit beschwerdefrei waren. Die dritte Studie erfolgte zur Validierung eines Instrumentes zur standardisierten Erfassung des Therapieerfolges bei der Urtikaria, dem Urtikaria Kontrolltest (UCT). In dieser Arbeit konnten wir u.a. eine sehr starke Korrelation zwischen dem UCT und dem Urtikariaaktivität feststellen. Es zeigte sich hier, dass eine Verbesserung des UCT Wertes um mindestens 3 Punkte im 0-16 Punkte umfassenden UCT, die „minimal clinically important difference“ MCID darstellt. Zusätzlich konnten wir bestätigen, dass bei csU Patienten ein UCT Wert von mindestens 12 Punkten für eine kontrollierte Urtikaria spricht. Das Ziel der letzten Arbeit war es, mögliche Prädikatoren für die Geschwindigkeit des Ansprechens nach Einleitung einer Therapie mit Omalizumab zu identifizieren. Von insgesamt 56 Patienten, die ein komplettes Ansprechen zeigten, waren 70% innerhalb von 8 Tagen beschwerdefrei (fast responder), die restlichen 30% benötigten 8 Tage bis 3 Monate für ein komplettes Ansprechen (slow responder). Hierbei zeigte sich, dass die Gruppe der slow responder überwiegend einen positiven Hauttest auf ihr eigenes Serum und v.a. einen positiven Basophilen-Freisetzungsassay aufwiesen. Dies ermöglicht einerseits den wahrscheinlichen Zeitpunkt des Therapieansprechens bereits im Vorfeld einer Therapie zu bestimmen, andererseits geben die Ergebnisse Hinweise darauf, dass bei den slow respondern eine Autoimmunität vom Typ IIb vorliegt, bei der Autoantikörper gegen den IgE-Rezeptor vorliegen. Hier besteht der Wirkmechanismus in der allmählichen Herunterregulation des IgE Rezeptors, im Gegensatz zu den fast responders, bei denen die Bindung und damit Eliminierung von IgE-Autoantikörpern die wesentliche Rolle zu spielen scheinen. Zusammengefasst zeigt die vorliegende Arbeit, dass Omalizumab eine wirksame, schnelle und sichere Therapie bei der CU darstellt. Auch nach einer erneuten Therapieeinleitung bleibt die Wirksamkeit und Sicherheit unverändert gut. Ein negativer BHRA kann als möglicher prädiktiver Faktor für ein schnelles Ansprechen auf eine Therapie mit Omalizumab verwendet werden., Urticaria is one of the most common diseases in dermatology. The present thesis aimed at validating new methods in the diagnostics of chronic urticaria (CU), characterizing the effects of omalizumab as an innovative therapy for CU and identifying possible predictors for therapeutic response. Four independent studies were performed for this purpose. In the first two retrospective studies the efficacy and safety of omalizumab in patients with CU were evaluated. These two studies showed, among other things, that 57% of chronic spontaneous urticaria (csU) patients were symptom-free within the first week after the first treatment, and that patients were symptom-free again after a short time after interruption of the treatment with omalizumab and after the re-initiation of treatment. The third study was conducted to validate an instrument for assessment of disease control, the Urticaria Control Test (UCT). In this work, we found a strong correlation between UCT and urticaria activity. It was shown that an improvement of the UCT value by at least 3 points in the 0-16 scale represents the "minimal clinically important difference" (MCID) of UCT. In addition, we confirmed that a UCT value of at least 12 points is the lowest value for a controlled urticaria in csU patients. The aim of the last paper was to identify possible predictors for the speed of response after initiation of omalizumab therapy. Of a total of 56 patients showing a complete response, 70% were symptom-free within 8 days (fast responder), the remaining 30% required 8 days to 3 months for a complete response (slow responder). The slow responder group predominantly had a positive autologous serum skin test and above all a positive basophil release assay. On the one hand, this can predict time to response prior to therapy, and on the other hand, the results indicate that slow responders have type IIb autoimmunity in which autoantibodies against the IgE receptor are present. The mechanism of action in these patients consists in the gradual downregulation of the IgE receptor, in contrast to the fast responders in which the binding and thus elimination of IgE autoantibodies seem to play the essential role. In summary, the present thesis shows that omalizumab is an effective, fast and safe therapy for CU patients. Negative BHRA can be used as a potential predictive factor for rapid response to omalizumab therapy and the UCT is the ideal tool to assess the level of control achieved.
- Published
- 2019
13. Histamin in der Interstitialflüssigkeit der befallenen und klinisch nicht befallenen Haut bei chronisch rezidivierender Urticaria.
- Author
-
Bork, K., König, W., and Böhm, G.
- Abstract
Copyright of Archives of Dermatological Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 1979
- Full Text
- View/download PDF
14. Urtikaria: Basiswissen für den HNO-Arzt
- Author
-
Daut, V., Staubach, P., Hörmann, K., Klimek, L., and Pfaar, O.
- Published
- 2012
- Full Text
- View/download PDF
15. Urtikaria: „From bench to bedside“
- Author
-
Magerl, M. and Maurer, M.
- Published
- 2007
- Full Text
- View/download PDF
16. Urticaria associated with Norovirus infection: report of two cases
- Author
-
Peter Altmeyer, I. Venten, Norbert H. Brockmeyer, Adriane Skaletz-Rorowski, and Anke Leiste
- Subjects
Male ,Urticaria ,viruses ,Dermatology ,medicine.disease_cause ,Diagnosis, Differential ,Feces ,fluids and secretions ,Viral envelope ,Dermatologic diseases ,medicine ,Humans ,Chronic urticaria ,Caliciviridae Infections ,biology ,Norovirus ,virus diseases ,Helicobacter pylori ,Middle Aged ,biology.organism_classification ,Genus Norovirus ,Virology ,digestive system diseases ,Gastroenteritis ,Immunology ,Acute Disease ,Chronic Disease ,Female - Abstract
Acute and chronic urticaria may be triggered by infection. Streptococci and Helicobacter pylori are the most frequent acute infectious causes. We present two cases in which we cultured Norovirus in the stool of patients with both acute and chronic urticaria. Noroviruses (genus Norovirus, family Caliciviridae) are a group of single stranded RNA, nonenveloped viruses which cause acute gastroenteritis in humans. Norovirus was recently approved as the official genus name for the group of viruses provisionally described as Norwalk-like viruses (NLV). Therapy is symptomatic. Noroviruses should be regarded as possible infectious trigger for dermatologic diseases. In seeking a focus of viral or bacterial infection for skin diseases with unknown origin, stool cultures should be part of the routine evaluation.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.